CXL: Corneal Collagen Cross-linking for Progressive Keratoconus
Study Details
Study Description
Brief Summary
Prospective, randomized multicenter study to determine the safety and effectiveness of performing cornea collagen cross-linking (CXL) using riboflavin and UVA light in eyes with progressive keratoconus.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 3 |
Detailed Description
This was a sham controlled study for the first three months. Patients had one eye designated as the study eye and were randomized to receive one of two study treatments (CXL or sham) in their study eye. The patients were evaluated at 1, 3, 6, and 12 months. At month 3 or later patients had the option of receiving CXL treatment in both the sham and non-study eye.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Active Comparator: Corneal Collagen Cross-linking (CXL) Treatment Group riboflavin ophthalmic solution and UVA irradiation |
Drug: riboflavin ophthalmic solution
riboflavin 0.1% ophthalmic solution (approximately 32 drops, or 1.6 mL)
Device: UVA Irradiation
UVA light (365 nm at an irradiance of 3 mW/cm2) for 30 minutes
Other Names:
|
Sham Comparator: Control Group riboflavin ophthalmic solution without UVA irradiation. |
Drug: riboflavin ophthalmic solution
riboflavin 0.1% ophthalmic solution (approximately 32 drops, or 1.6 mL)
|
Outcome Measures
Primary Outcome Measures
- Mean Change From Baseline in Maximum Keratometry (Kmax) [baseline,12 months]
The primary efficacy parameter was corneal curvature, as measured by maximum keratometry (Kmax) in the study eyes. Study success was defined as a difference of ≥1 D in the mean change in Kmax from baseline to 12 months between the CXL group and control group. Keratometry was measured manually and by pentacam.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Diagnosis of keratoconus
-
Documented progression over previous 24 months
-
Decreased BSCVA
-
Must complete all study visits
Exclusion Criteria:
-
Prior corneal surgery or Intacs
-
History of delayed wound healing
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Shiley Eye Center | La Jolla | California | United States | 92093 |
2 | Gordon -Weiss Vision Institute | San Diego | California | United States | 91222 |
3 | Center for Excellence in Eye Care | Miami | Florida | United States | 33176 |
4 | Price Vision Group | Indianapolis | Indiana | United States | 46260 |
5 | Durrie Vision | Kansas City | Kansas | United States | 66211 |
6 | Wilmer Eye Institute at Johns Hopkins University | Baltimore | Maryland | United States | 21287 |
7 | Minnesota Eye Consultants | Minneapolis | Minnesota | United States | 55404 |
8 | Cornea & Laser Eye Institute; Hersh Vision Group | Teaneck | New Jersey | United States | 07666 |
9 | Edward Harkness Eye Institute at Columbia University Medical Center | New York | New York | United States | 10032 |
10 | Ophthalmic Consultants of Long Island | Rockville Centre | New York | United States | 11570 |
Sponsors and Collaborators
- Glaukos Corporation
Investigators
- Principal Investigator: Peter Hersh, MD, Cornea and Laser Institute
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- UVX-002
Study Results
Participant Flow
Recruitment Details | |
---|---|
Pre-assignment Detail |
Arm/Group Title | Corneal Collagen Cross-linking (CXL) Treatment Group | Control Group |
---|---|---|
Arm/Group Description | riboflavin ophthalmic solution and UVA irradiation (365 nm at an irradiance of 3 mW/cm2) for 30 minutes | riboflavin ophthalmic solution without UVA irradiation |
Period Title: Overall Study | ||
STARTED | 73 | 74 |
COMPLETED | 65 | 62 |
NOT COMPLETED | 8 | 12 |
Baseline Characteristics
Arm/Group Title | Corneal Collagen Cross-linking (CXL) Treatment Group | Control Group | Total |
---|---|---|---|
Arm/Group Description | riboflavin ophthalmic solution and UVA irradiation (365 nm at an irradiance of 3 mW/cm2) for 30 minutes | riboflavin ophthalmic solution without UVA irradiation | Total of all reporting groups |
Overall Participants | 73 | 74 | 147 |
Age (Count of Participants) | |||
<=18 years |
7
9.6%
|
3
4.1%
|
10
6.8%
|
Between 18 and 65 years |
66
90.4%
|
71
95.9%
|
137
93.2%
|
>=65 years |
0
0%
|
0
0%
|
0
0%
|
Sex: Female, Male (Count of Participants) | |||
Female |
19
26%
|
24
32.4%
|
43
29.3%
|
Male |
54
74%
|
50
67.6%
|
104
70.7%
|
Ethnicity (NIH/OMB) (Count of Participants) | |||
Hispanic or Latino |
7
9.6%
|
3
4.1%
|
10
6.8%
|
Not Hispanic or Latino |
31
42.5%
|
36
48.6%
|
67
45.6%
|
Unknown or Not Reported |
35
47.9%
|
35
47.3%
|
70
47.6%
|
Race (NIH/OMB) (Count of Participants) | |||
American Indian or Alaska Native |
0
0%
|
0
0%
|
0
0%
|
Asian |
0
0%
|
1
1.4%
|
1
0.7%
|
Native Hawaiian or Other Pacific Islander |
0
0%
|
0
0%
|
0
0%
|
Black or African American |
7
9.6%
|
7
9.5%
|
14
9.5%
|
White |
54
74%
|
61
82.4%
|
115
78.2%
|
More than one race |
0
0%
|
0
0%
|
0
0%
|
Unknown or Not Reported |
12
16.4%
|
5
6.8%
|
17
11.6%
|
Outcome Measures
Title | Mean Change From Baseline in Maximum Keratometry (Kmax) |
---|---|
Description | The primary efficacy parameter was corneal curvature, as measured by maximum keratometry (Kmax) in the study eyes. Study success was defined as a difference of ≥1 D in the mean change in Kmax from baseline to 12 months between the CXL group and control group. Keratometry was measured manually and by pentacam. |
Time Frame | baseline,12 months |
Outcome Measure Data
Analysis Population Description |
---|
The ITT (intent to treat) population consisted of all treated subjects, analyzed according to the treatment actually received. For the sham study eyes that received CXL treatment after baseline, the last Kmax measurement recorded prior to receiving CXL treatment was used in the analysis for later time points. |
Arm/Group Title | Corneal Collagen Cross-linking (CXL) Treatment Group | Control Group |
---|---|---|
Arm/Group Description | riboflavin ophthalmic solution and UVA irradiation (365 nm at an irradiance of 3 mW/cm2) for 30 minutes | riboflavin ophthalmic solution without UVA irradiation |
Measure Participants | 73 | 74 |
Mean (Standard Deviation) [diopters] |
-1.7
(4.7)
|
0.6
(2.8)
|
Adverse Events
Time Frame | 3 months | |||
---|---|---|---|---|
Adverse Event Reporting Description | ||||
Arm/Group Title | Corneal Collagen Cross-linking (CXL) Treatment Group | Control Group | ||
Arm/Group Description | riboflavin ophthalmic solution and UVA irradiation (365 nm at an irradiance of 3 mW/cm2) for 30 minutes | riboflavin ophthalmic solution without UVA irradiation | ||
All Cause Mortality |
||||
Corneal Collagen Cross-linking (CXL) Treatment Group | Control Group | |||
Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
Total | / (NaN) | / (NaN) | ||
Serious Adverse Events |
||||
Corneal Collagen Cross-linking (CXL) Treatment Group | Control Group | |||
Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
Total | 0/73 (0%) | 3/74 (4.1%) | ||
Eye disorders | ||||
ulcerative keratitis | 0/73 (0%) | 0 | 1/74 (1.4%) | 1 |
Infections and infestations | ||||
Appendicitis | 0/73 (0%) | 0 | 1/74 (1.4%) | 1 |
Injury, poisoning and procedural complications | ||||
infectious cat bite | 0/73 (0%) | 0 | 1/74 (1.4%) | 1 |
Other (Not Including Serious) Adverse Events |
||||
Corneal Collagen Cross-linking (CXL) Treatment Group | Control Group | |||
Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
Total | 57/73 (78.1%) | 25/74 (33.8%) | ||
Eye disorders | ||||
Corneal opacity | 35/73 (47.9%) | 43 | 1/74 (1.4%) | 1 |
Eye pain | 13/73 (17.8%) | 13 | 3/74 (4.1%) | 3 |
Punctate keratitis | 13/73 (17.8%) | 16 | 8/74 (10.8%) | 8 |
Corneal striae | 11/73 (15.1%) | 11 | 5/74 (6.8%) | 5 |
Corneal epithelial defect | 10/73 (13.7%) | 11 | 1/74 (1.4%) | 1 |
Vision blurred | 9/73 (12.3%) | 12 | 1/74 (1.4%) | 1 |
Conjunctival hyperaemia | 7/73 (9.6%) | 7 | 1/74 (1.4%) | 1 |
Photophobia | 6/73 (8.2%) | 6 | 0/74 (0%) | 0 |
Eyelid oedema | 5/73 (6.8%) | 5 | 0/74 (0%) | 0 |
Visual acuity reduced | 5/73 (6.8%) | 5 | 6/74 (8.1%) | 8 |
Dry Eye | 4/73 (5.5%) | 5 | 2/74 (2.7%) | 2 |
Eye irritation | 4/73 (5.5%) | 4 | 1/74 (1.4%) | 1 |
Eye oedema | 4/73 (5.5%) | 4 | 0/74 (0%) | 0 |
Anterior chamber flare | 3/73 (4.1%) | 3 | 0/74 (0%) | 0 |
Corneal disorder | 3/73 (4.1%) | 3 | 0/74 (0%) | 0 |
Lacrimation increased | 3/73 (4.1%) | 3 | 0/74 (0%) | 0 |
Corneal oedema | 2/73 (2.7%) | 2 | 0/74 (0%) | 0 |
Diplopia | 2/73 (2.7%) | 2 | 1/74 (1.4%) | 1 |
Foreign body sensation in eye | 2/73 (2.7%) | 2 | 0/74 (0%) | 0 |
Glare | 2/73 (2.7%) | 2 | 1/74 (1.4%) | 1 |
Ocular hyperaemia | 2/73 (2.7%) | 2 | 1/74 (1.4%) | 1 |
Visual impairment | 2/73 (2.7%) | 2 | 1/74 (1.4%) | 1 |
Corneal scar | 2/73 (2.7%) | 2 | 2/74 (2.7%) | 2 |
Nervous system disorders | ||||
Headache | 2/73 (2.7%) | 2 | 0/74 (0%) | 0 |
Limitations/Caveats
More Information
Certain Agreements
Principal Investigators are NOT employed by the organization sponsoring the study.
Site has the right to publish or communicate study results upon the earlier of: (a) publication of a multi-center publication of the Study results coordinated by Sponsor; or (b) submission of the Study data by Sponsor to the FDA; provided that the Sponsor reviews the proposed communication of results within ninety (90) days in advance of its release. Sponsor can request delay of publication or data release to allow for filing of patent application prior to the publication or release.
Results Point of Contact
Name/Title | Vineeta Belanger, VP of Clinical Affairs |
---|---|
Organization | Avedro, Inc. |
Phone | 781-768-3459 |
vbelanger@avedro.com |
- UVX-002